Physician

Paul T Adams, M.D.

According to 2025 Medicare claims, Paul Adams, M.D. (NPI: 1811952591) practices hematology/oncology in the Flint, MI market, with the plurality of this provider's patient population coming from Genesee, MI. This provider's primary affiliated billing organization is GENESEE HEMATOLOGY-ONCOLOGY, P.C. (NPI: 1902977101; TIN: 382278871) and primary practice location at 48503-2044. Adams is affiliated with the Genesys PHO, L.L.C. (ACO ID: A2597) and Mosaic ACO (ACO ID: A5033), participating under the MSSP model.

Adams' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 449 traditional Medicare patients, billed 73,569 HCPCS/CPT codes, and received $948,130 in Medicare payments. The top billing code was 99222 (Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes). Part D data shows 2,036 prescription claims across 315 beneficiaries totaling $7,236,213 in drug costs, led by Revlimid (Lenalidomide). 2020 DME data shows 35 claims. Open Payments data shows 60 records totaling $6,004. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $1,302,649 and ending at $948,130. Concurrently, Part D prescription costs have risen steadily, from $3,032,861 to $7,236,213. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $1,959 to $802.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	615	69,834	$1,302,649
2016	630	88,901	$1,290,320
2017	672	98,149	$1,178,123
2018	659	107,820	$1,649,982
2019	568	72,323	$1,164,519
2020	557	83,613	$1,458,576
2021	556	82,411	$1,292,698
2022	531	68,749	$1,037,186
2023	508	86,251	$1,333,966
2024	449	73,569	$948,130

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	365	1,911	$3,032,861
2016	371	2,200	$3,895,281
2017	354	2,092	$4,380,900
2018	395	2,150	$5,395,158
2019	326	1,942	$5,858,077
2020	309	1,990	$6,049,357
2021	289	1,822	$6,684,654
2022	300	1,740	$7,033,589
2023	309	1,825	$6,563,698
2024	315	2,036	$7,236,213

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	39	$1,700
2016	N/R	68	$19,197
2017	N/R	N/R	N/R
2018	N/R	57	$2,483
2019	N/R	32	$940
2020	N/R	35	$3,205
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	76	83	$93
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	209	551	$86
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	58	90	$45
96372	Injection of drug or substance under skin or into muscle	61	206	$11
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	314	804	$7

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	75	2,044	$1,662,676
Lenalidomide	Lenalidomide	59	1,624	$973,779
Xtandi	Enzalutamide	62	1,860	$864,819
Venclexta	Venetoclax	40	1,194	$516,051
Ojjaara	Momelotinib Dihydrochloride	14	420	$395,063

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	58	$1,129	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	2	$4,875	E.R. Squibb & Sons, L.L.C.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Paul T. Adams, M.D.?

Tedicare shows public-source Medicare data for Paul T. Adams, M.D. (NPI 1811952591), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Paul T. Adams, M.D. have ACO affiliation data?

Paul T. Adams, M.D. is shown with ACO affiliation data for Genesys PHO, L.L.C. (MSSP, ACO ID A2597) and Mosaic ACO (MSSP, ACO ID A5033).

What billing organization is linked to Paul T. Adams, M.D.?

Paul T. Adams, M.D. is linked to GENESEE HEMATOLOGY-ONCOLOGY, P.C. (billing NPI 1902977101) in the available physician profile data.

Does Paul T. Adams, M.D. have Open Payments data?

Paul T. Adams, M.D. has 60 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.